Market Intelligence, Clinical Progress, and High-Purity Reagents for Germ Cell Biology and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DAZL drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DAZL Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Theoretical MW. |
View DAZL Products |
| Gene Delivery | DAZL Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View DAZL Products |
| Benchmark Ab | Anti-DAZL Recombinant Antibody Recombinant positive control. |
View DAZL Products |
| Validator | DAZL siRNA Set For knockdown verification. |
View DAZL Products |
| Related Target A | BOLL Homolog family member involved in translational regulation during spermatogenesis; critical for counter-screening. |
View BOLL Products |
| Related Target B | PUM2 Pumilio homolog 2; physically interacts with DAZL to cooperatively regulate mRNA translation. |
View PUM2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Specificity against homologous family members (DAZ, BOLL) | Recombinant DAZL, DAZ, and BOLL homolog panel strictly verified by mass spectrometry and sequence validation |
| RNA-binding activity assay setup | High purity, RNase-free recombinant DAZL protein preserving RNA-binding domain (RRM) conformation |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live DAZL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DAZL therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule inhibitors targeting its RNA-binding pocket. As first-generation therapies reach the clinic, the next wave of R&D is targeting DAZL as an oncofetal antigen in germ cell tumors and refractory solid malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Academic Consortia, Biotech Startups | Male Contraception, Germ Cell Tumors | RNA-Binding Inhibition Assay (Need RNase-free recombinant protein) |
| RNA Therapeutics (ASO/siRNA) | RNAi Therapeutics Developers | Ovarian Cancer, Reproductive Disorders | In vitro knockdown validation (Need high-titer Lentivirus & siRNA sets) |
| Cancer Vaccine / Immunotherapy | Immuno-oncology Biotechs | Testicular Germ Cell Tumors | Target expression validation (Need sequence-verified benchmark antibodies) |